Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$4.82 - $7.7 $1.62 Million - $2.59 Million
-336,008 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.0 - $16.98 $445,242 - $1.26 Million
-74,207 Reduced 18.09%
336,008 $2.2 Million
Q4 2021

Feb 14, 2022

SELL
$15.19 - $29.33 $3.92 Million - $7.56 Million
-257,774 Reduced 38.59%
410,215 $6.72 Million
Q3 2021

Nov 15, 2021

SELL
$27.35 - $37.28 $3.18 Million - $4.34 Million
-116,355 Reduced 14.83%
667,989 $19.4 Million
Q2 2021

Aug 16, 2021

SELL
$26.5 - $38.23 $6.5 Million - $9.38 Million
-245,368 Reduced 23.83%
784,344 $27.2 Million
Q1 2021

May 14, 2021

BUY
$29.83 - $56.81 $11.5 Million - $21.9 Million
384,752 Added 59.66%
1,029,712 $32.5 Million
Q4 2020

Mar 01, 2021

BUY
$39.12 - $54.99 $140,323 - $197,249
3,587 Added 0.56%
644,960 $30.5 Million
Q3 2020

Nov 13, 2020

BUY
$29.21 - $46.58 $6.78 Million - $10.8 Million
232,255 Added 56.77%
641,373 $29.9 Million
Q2 2020

Aug 14, 2020

BUY
$33.67 - $40.0 $9.01 Million - $10.7 Million
267,619 Added 189.13%
409,118 $14.8 Million
Q1 2020

May 15, 2020

SELL
$24.28 - $49.8 $549,213 - $1.13 Million
-22,620 Reduced 13.78%
141,499 $5.02 Million
Q4 2019

Feb 14, 2020

BUY
$24.84 - $45.46 $4.08 Million - $7.46 Million
164,119 New
164,119 $7.46 Million

Others Institutions Holding ZYME

About Zymeworks Inc.


  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $949M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.